Verastem Oncology announced the appointment of Matthew E. Ros as chief operating officer. In this role, Mr Ros will report to Dan Paterson, president and chief executive officer, to prepare for a mid-2025 product launch and the transition into a commercial-stage company, while continuing to advance clinical programs and partnerships to address cancers driven by the RAS/MAPK-pathway.
Company Information
Company
Verastem Oncology
Location
117 Kendrick Street, Suite 500
Needham, Massachusetts, United States
About
Verastem Oncology (Nasdaq: VSTM) is a late-stage development biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with RAS/MAPK pathway-driven cancers. Our pipeline is focused on novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including RAF/MEK inhibition and FAK inhibition.
Fundz sees it the moment Verastem Oncology changes its leadership, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
NeedhamBiotechnologyHealthcareHealth CareTherapeuticsBiopharma